Brief: Alteogen's Gastric Cancer Drug Gets FDA Approval For Orphan Drug Designation
06/08/2018 14:18
Aug 6 (Reuters) - Alteogen Inc 196170.KQ :
* ALTEOGEN GETS FDA APPROVAL FOR ORPHAN DRUG DESIGNATION
WITH AN
ANTIBODY-DRUG CONJUGATE FOR GASTRIC CANCER
Source text for Eikon: urn:newsml:reuters.com:*:nBw7BSd92a
Further company coverage: 196170.KQ
Recent news on Alteogen
See all newsBrief: Alteogen Enters Into A License Agreement With Biogen For Development And Commercialization Of Hybrozyme™-Based Subcutaneous Biologics
Brief: Alteogen Signs Licensing Deal With Biogen International For Alt-B4
Brief: Alteogen 2025 Operating Profit 115 Billion Won, Up 275% From Year Earlier
Brief: Alteogen Signs $285 Million Contract With Gsk Unit
Brief: Alteogen Receives Positive CHMP Opinion For Aflibercept Biosimilar, 'EYLUXVI® (ALT-L9)'